

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

624-mel

RRID:CVCL_8054

Type: Cell Line

Proper Citation

RRID:CVCL_8054

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_8054

Proper Citation: RRID:CVCL_8054

Description: Cell line 624-mel is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Melanoma

Defining Citation: [PMID:8027550](#), [PMID:8081556](#), [PMID:8537970](#), [PMID:9759882](#), [PMID:10048982](#), [PMID:10754339](#), [PMID:15467732](#), [PMID:15592718](#), [PMID:19340423](#), [PMID:23851445](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27600516](#)

Comments: From: Rosenberg, Steven A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: 624-mel

Synonyms: 624-MEL, 624 MEL, 624 Mel, 624 mel, 624mel, 624MEL, 624, Mel-624, Mel624, MEL624

Cross References: BTO:BTO_0002951, EFO:EFO_0006359, ArrayExpress:E-MTAB-2706, BioGRID_ORCS_Cell_line:754, BioSample:SAMN03471309, cancercellines:CVCL_8054, CGH-DB:9301-4, ChEMBL-Cells:ChEMBL3885941, Cosmic:876683, Cosmic:905214, Cosmic:1303044, Cosmic:1559441, Cosmic:2163793, EGA:EGAS00001000610, EGA:EGAS00001002554, ESTDAB:ESTDAB-049, GEO:GSM206438, GEO:GSM274692, PharmacDB:624mel_23_2019, PubChem_Cell_line:CVCL_8054, Wikidata:Q54604356

ID: CVCL_8054

Record Creation Time: 20220427T215057+0000

Record Last Update: 20260913T011837+0000

Ratings and Alerts

No rating or validation information has been found for 624-mel.

No alerts have been found for 624-mel.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Franken GA, et al. (2026) Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD-L1 in melanoma. Molecular oncology.

S??varsson T, et al. (2026) Enhanced IFN γ response in dedifferentiated melanoma cells is due to chromatin remodeling as revealed by ATAC-seq. Cell communication and signaling : CCS, 24(1).

van Eck van der Sluijs J, et al. (2026) Sialic acid cis-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity. Oncoimmunology, 15(1), 2649988.

Pyun WY, et al. (2026) Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. Cancer research, 86(5), 1194.

Magno JC, et al. (2026) Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses. Cancer research, 86(11), 2688.

Zhang Y, et al. (2025) A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma. Cell reports, 44(12), 116675.

Allard D, et al. (2025) Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis. Cancer research, 85(4), 692.

Greiner D, et al. (2025) Human CSPG4-targeting CAR-macrophages inhibit melanoma growth. Oncogene, 44(22), 1665.

Alsubaiti A, et al. (2025) Tumor cell spheroid-induced suppression of primary human cytotoxic T cells as a scalable in vitro model of exhaustion. *Immunotherapy advances*, 5(1), Itaf023.

Dong B, et al. (2024) NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. *Cancer immunology research*, 12(10), 1421.

Becker AMD, et al. (2024) Inhibition of CSF-1R and IL-6R prevents conversion of cDC2s into immune incompetent tumor-induced DC3s boosting DC-driven therapy potential. *Cell reports. Medicine*, 5(2), 101386.

Wenthe J, et al. (2023) Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models. *Journal of translational medicine*, 21(1), 506.

Sun R, et al. (2023) ROTACs leverage signaling-incompetent R-spondin for targeted protein degradation. *Cell chemical biology*, 30(7), 739.

Kenski JCN, et al. (2023) An adverse tumor-protective effect of IDO1 inhibition. *Cell reports. Medicine*, 4(2), 100941.

Immisch L, et al. (2023) Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors. *Frontiers in immunology*, 14, 1119498.

Dolton G, et al. (2023) Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. *Cell*, 186(16), 3333.

Margolis N, et al. (2022) Adenosine-Deaminase-Acting-on-RNA-1 Facilitates T-cell Migration toward Human Melanoma Cells. *Cancer immunology research*, 10(9), 1127.

Huang L, et al. (2021) Targeting Pan-ETS Factors Inhibits Melanoma Progression. *Cancer research*, 81(8), 2071.

Willimsky G, et al. (2021) In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo. *eLife*, 10.

Creelan BC, et al. (2021) Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. *Nature medicine*, 27(8), 1410.